Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Surface-stabilized nonferromagnetic ordering of a layered ferromagnetic manganite.
Nascimento VB, Freeland JW, Saniz R, Moore RG, Mazur D, Liu H, Pan MH, Rundgren J, Gray KE, Rosenberg RA, Zheng H, Mitchell JF, Freeman AJ, Veltruska K, Plummer EW. Nascimento VB, et al. Among authors: moore rg. Phys Rev Lett. 2009 Nov 27;103(22):227201. doi: 10.1103/PhysRevLett.103.227201. Epub 2009 Nov 24. Phys Rev Lett. 2009. PMID: 20366122
Interfacially enhanced superconductivity in Fe(Te,Se)/Bi4Te3 heterostructures.
Chen AH, Lu Q, Hershkovitz E, Crespillo ML, Mazza AR, Smith T, Ward TZ, Eres G, Gandhi S, Mahfuz MM, Starchenko V, Hattar K, Lee JS, Kim H, Moore RG, Brahlek M. Chen AH, et al. Among authors: moore rg. Adv Mater. 2024 May 8:e2401809. doi: 10.1002/adma.202401809. Online ahead of print. Adv Mater. 2024. PMID: 38717569
A whole food, plant-based randomized controlled trial in metastatic breast cancer: feasibility, nutrient, and patient-reported outcomes.
Campbell EK, Campbell TM, Culakova E, Blanchard L, Wixom N, Guido JJ, Fetten J, Huston A, Shayne M, Janelsins MC, Mustian KM, Moore RG, Peppone LJ. Campbell EK, et al. Among authors: moore rg. Breast Cancer Res Treat. 2024 Mar 30. doi: 10.1007/s10549-024-07284-z. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 38553649
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.
González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR, Monk BJ. González-Martín A, et al. Among authors: moore rg. Future Oncol. 2024 Mar 19. doi: 10.2217/fon-2023-0782. Online ahead of print. Future Oncol. 2024. PMID: 38501262 Free article. Review.
267 results